PCM
MRNS

Penserra Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Penserra Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-835
Closed -$9K – 1594
2021
Q3 		$9K Hold
835
– – ﹤0.01% 1373
2021
Q2 		$14K Buy
835
+25
+3% +$402 ﹤0.01% 1244
2021
Q1 		$12K Buy
810
+110
+16% +$1.59K ﹤0.01% 1017
2020
Q4 		$8K Buy
+700
New +$9.76K ﹤0.01% 954

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Penserra Capital Management's MRNS Position: Q4 2021 in Review

Penserra Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2021, closing a stake of 835 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in MRNS in Q4 2020 and held it in 4 quarters. The position peaked at $14K in Q2 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q4 2021.

  • Penserra Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 835 Marinus Pharmaceuticals, Inc shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Marinus Pharmaceuticals, Inc position peaked at $14K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.